LONDON (Aug 9): The European Medicines Agency (EMA) has started a rolling review of a variant-adapted Covid-19 vaccine from Pfizer and BioNTech, it said on Tuesday.
The so-called bivalent vaccine targets two strains of the SARS-CoV-2 virus behind Covid-19 — the original strain first identified in China, and the Omicron offshoots BA.4/5 that are currently behind most cases in Europe.
A rolling review means the EMA assesses the data as it becomes available, and the process continues until there is enough data for a formal marketing application.
Last month, the EMA said it had begun a rolling review of another version of the companies’ shot which targets the original SARS-CoV-2 strain and Omicron subvariant BA.1.
While existing coronavirus vaccines continue to provide good protection against hospitalisation and death, vaccine effectiveness has taken a hit as the virus has evolved.
European Union officials plan to use bivalent shots in their autumn vaccination campaign, with most cases in the region now linked to the BA.5 variant.
The EMA expects new Covid-19 variant-adapted vaccines to be approved by September, but has signalled it is open to using shots targeting the older BA.1 variant for that campaign, given the shots targeting the newer BA.4 and BA.5 strains are further behind in clinical development.
- US FDA fully approves Pfizer-BioNTech as first COVID-19 vaccine
- New Variant of COVID-19 Detected in South Africa
- F.D.A. Fully Approves Pfizer-BioNTech’s Vaccine, a First for a Covid-19 Shot
- Pfizer Developing Specialized Vaccine Targeting Delta Variant of COVID-19
- EU Health Body Urges Countries to Focus on Covid-19 Vaccines First Not Booster Shots
- Fauci warns the US is 'going to see a lot more vaccine mandates' after the FDA granted the Pfizer COVID-19 shot full approval
- Japan eyes mixed use of Covid-19 shots to speed vaccine rollout
- EU Health Agencies See ‘No Urgent Need’ For COVID-19 Boosters Among Fully Vaccinated
- Dr. Anthony Fauci says the U.S. is 'keeping a very close eye' on Mu variant of COVID-19 but it is 'not an immediate threat'
- Teens Get First COVID-19 Shots As State Encourages Vaccinations Before School
- Delta variant doubles Covid-19 hospitalization risk, study finds
- About 14 million in U.S. get first COVID-19 shot in August, up from July
- The Latest: Tehran thieves attack car, steal COVID-19 shots
- Japan eyes mixed use of COVID-19 shots to speed vaccine rollout
- Japan eyes mixed use of Covid-19 shots to speed vaccine roll-out
- Biden to lay out new strategy against delta variant of COVID-19
- More job listings require candidates to get their COVID-19 shots
- COVID-19: Pfizer booster shot to start by September 20 in US, hints Anthony Fauci
- New Zealand to Lift Many COVID-19 Restrictions
- Overcrowded Aboriginal Housing Highlighted as Australia Races to Help COVID-19-Hit Outback Town
EU regulator begins review of Pfizer-BioNTech's variant-adapted Covid-19 shot have 436 words, post on www.theedgemarkets.com at August 9, 2022. This is cached page on Business News. If you want remove this page, please contact us.